1518. Assessment of Antibiotic Prescribing in the Outpatient Setting for Uncomplicated Urinary Tract Infection in Pediatrics (UTIP Trial) with a Review of Local E. coli Susceptibilities
Abstract
Abstract Background The IDSA recommends the use of sulfamethoxazole-trimethoprim (SXT) as empiric therapy (E/T) for uncomplicated urinary tract infections (UTI) in areas where the resistance rate is <20%. We sought to describe the susceptibility patterns of urinary E. coli isolates from an urban pediatric outpatient centers/schools and analyze antibiotic (ABX) prescribing to encourage use of cephalexin (LEX) as E/T for uncomplicated UTI. Methods This is a retrospective analysis of outpatient UTI management from December 2016 to April 2017. Patients were identified using ICD-10 codes related to UTI or associated symptoms, and chart review was performed by electronic medical record (EMR). Demographic, clinical and laboratory data were collected. The primary endpoint was the choice of ABX for E/T for UTI. Fisher’s Exact, and χ2 tests were used for data analysis. Results We identified 1,138 patients with appropriate ICD-10 codes and a retrievable EMR. Of those 1,138, 882 (78%) received no ABXs, 14 (1%) received an ABX for other indications, and 242 (21%) were prescribed an ABX for UTI E/T. There were 834 (73.3%) female patients and the median age was 11 years (range: 1 week to 21 years). The top 4 ABXs prescribed for E/T were SXT 83/242 (34.3%), nitrofurantoin 44/242 (18.2%), LEX 27/242 (11.2%), and ciprofloxacin 21/242 (8.7%). LEX was prescribed 64.3% in the youngest and 8.8% in the oldest age groups for E/T UTIs, P < 0.001 (Table 1). The rate of return to the clinic or…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.